References

• 2016Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 20156,217 cited
• 2018Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20174,086 cited
• 2016Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses3,063 cited
• 2017Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 20162,078 cited
• 2012Model Parameter Estimation and Uncertainty Analysis886 cited
• 2008Health state utilities for non small cell lung cancer407 cited
• 2011Improved curve fits to summary survival data: application to economic evaluation of health technologies308 cited
• 2016Health state utilities in non–small cell lung cancer: An international study304 cited
• 2017Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States142 cited
• 2012Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting108 cited
• 2017The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC90 cited